Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 6/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244842 | 0.88 | TAAR1 (0.52) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL4609264 | 0.86 | HDAC1 (0.53) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL3245715 | 0.85 | HDAC1 (0.51) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL9206133 | 0.82 | GFER (0.36) | TAAR1MAOBKMT2AFFAR1 | |
| SCHEMBL934227 | 0.79 | TAAR1 (0.73) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL6140813 | 0.79 | TAAR1 (0.55) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL4716530 | 0.79 | TAAR1 (0.55) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL1838110 | 0.79 | DAO (0.45) | TAAR1MIFDAOIDO1 | |
| SCHEMBL3246600 | 0.78 | TAAR1 (0.54) | TAAR1MIFMAOBDAOHDAC1 | |
| SCHEMBL5541700 | 0.77 | TAAR1 (0.61) | TAAR1MIFMAOBDAOHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| EP-3219717-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | disclosed |
| US-4275219-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4145441-A | SYMPATHOMIMETIC AMINES EXHIBITING ANTI-HEMORRHOIDAL ACTIVITY | INTERX RESEARCH CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4094983-A | \"KETO\" SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4035405-A | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | TAAR1 494/4885MIF 1978/4885MAOB 607/4885 |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | TAAR1 335/4885MIF 1748/4885MAOB 448/4885 |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | TAAR1 335/4885MIF 1748/4885MAOB 448/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | TAAR1 335/4885MIF 1748/4885MAOB 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.